RxDoctor Payments Data

Gary Fitzgerald, MD

Family Medicine · Terre Haute, INNPI 1467443838

Payments from drug & device makers

$1,687in general payments, 2019–2025

Across 74 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$599
  • Lilly USA, LLC$215
  • AbbVie$186
  • Astellas Pharma US Inc$170
  • Pfizer$165
  • Bayer$123
  • plus $229 from 9 others

What the payments were for

  • Food & beverage$1,687100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,687 in reported general payments places this provider in the 65th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$101,553
Medicare patients
227
Services billed
2,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$66,587
TrulicityDulaglutide48$59,228
OzempicSemaglutide47$58,830
MounjaroTirzepatide45$55,008
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$30,789
JardianceEmpagliflozin14$24,002
MyrbetriqMirabegron15$19,955
RybelsusSemaglutide15$19,073
VraylarCariprazine Hcl12$17,011
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$15,837
XareltoRivaroxaban13$15,538
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$11,381
Tresiba Flextouch U-100Insulin Degludec16$9,893
Lantus SolostarInsulin Glargine,hum.Rec.Anlog40$3,602
Pantoprazole Sodium316$3,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$215$114,23693 claims
Novo NordiskOzempic, Rybelsus$599$77,90362 claims
PfizerEliquis$165$66,58753 claims
GSKTrelegy Ellipta$30$30,78938 claims
Astellas Pharma US IncMyrbetriq$170$19,95515 claims
AbbVieVraylar, Synthroid$186$17,97936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Terre Haute

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →